Longevity and determinants of protective humoral immunity after pandemic influenza infection
Antibodies to influenza hemagglutinin are the primary correlate of protection against infection. The strength and persistence of this immune response influences viral evolution and consequently the nature of influenza epidemics. However, the durability and immune determinants of induction of humoral immunity after primary influenza infection remain unclear. The spread of a novel H1N1 (A[H1N1]pdm09) virus in 2009 through an unexposed population offered a natural experiment to assess the nature and longevity of humoral immunity after a single primary influenza infection. We followed A(H1N1)pdm09-seronegative adults through two influenza seasons (2009-2011) as they developed A(H1N1)pdm09 influenza infection or were vaccinated. Antibodies to A(H1N1)pdm09 virus were measured by hemagglutination-inhibition assay in individuals with paired serum samples collected preinfection and postinfection or vaccination to assess durability of humoral immunity. Preexisting A(H1N1)pdm09-specific multicytokine-secreting CD4 and CD8 T cells were quantified by multiparameter flow cytometry to test the hypothesis that higher frequencies of CD4(+) T-cell responses predict stronger antibody induction after infection or vaccination. Antibodies induced by natural infection persisted at constant high titer for a minimum of approximately 15 months. Contrary to our initial hypothesis, the fold increase in A(H1N1)pdm09-specific antibody titer after infection was inversely correlated to the frequency of preexisting circulating A(H1N1)pdm09-specific CD4(+)IL-2(+)IFN-γ(-)TNF-α(-) T cells (r = -0.4122; P = 0.03). The longevity of protective humoral immunity after influenza infection has important implications for influenza transmission dynamics and vaccination policy, and identification of its predictive cellular immune correlate could guide vaccine development and evaluation..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:191 |
|---|---|
| Enthalten in: |
American journal of respiratory and critical care medicine - 191(2015), 3, Seite 325-332 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sridhar, Saranya [VerfasserIn] |
|---|
| Links: |
Volltext |
|---|
| RVK: |
|---|
| doi: |
10.1164/rccm.201410-1798OC |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1964567955 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1964567955 | ||
| 003 | DE-627 | ||
| 005 | 20230714162558.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1164/rccm.201410-1798OC |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1964567955 | ||
| 035 | |a (DE-599)GBVOLC1964567955 | ||
| 035 | |a (PRQ)p1897-f662f82848f05fb401d12d19544b90a92fbfa436ea1d35dce3d673f0eb93c2b10 | ||
| 035 | |a (KEY)0032313620150000191000300325longevityanddeterminantsofprotectivehumoralimmunit | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 21200 |q AVZ |2 rvk | ||
| 100 | 1 | |a Sridhar, Saranya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Longevity and determinants of protective humoral immunity after pandemic influenza infection |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Antibodies to influenza hemagglutinin are the primary correlate of protection against infection. The strength and persistence of this immune response influences viral evolution and consequently the nature of influenza epidemics. However, the durability and immune determinants of induction of humoral immunity after primary influenza infection remain unclear. The spread of a novel H1N1 (A[H1N1]pdm09) virus in 2009 through an unexposed population offered a natural experiment to assess the nature and longevity of humoral immunity after a single primary influenza infection. We followed A(H1N1)pdm09-seronegative adults through two influenza seasons (2009-2011) as they developed A(H1N1)pdm09 influenza infection or were vaccinated. Antibodies to A(H1N1)pdm09 virus were measured by hemagglutination-inhibition assay in individuals with paired serum samples collected preinfection and postinfection or vaccination to assess durability of humoral immunity. Preexisting A(H1N1)pdm09-specific multicytokine-secreting CD4 and CD8 T cells were quantified by multiparameter flow cytometry to test the hypothesis that higher frequencies of CD4(+) T-cell responses predict stronger antibody induction after infection or vaccination. Antibodies induced by natural infection persisted at constant high titer for a minimum of approximately 15 months. Contrary to our initial hypothesis, the fold increase in A(H1N1)pdm09-specific antibody titer after infection was inversely correlated to the frequency of preexisting circulating A(H1N1)pdm09-specific CD4(+)IL-2(+)IFN-γ(-)TNF-α(-) T cells (r = -0.4122; P = 0.03). The longevity of protective humoral immunity after influenza infection has important implications for influenza transmission dynamics and vaccination policy, and identification of its predictive cellular immune correlate could guide vaccine development and evaluation. | ||
| 540 | |a Nutzungsrecht: Copyright © 2015 by the American Thoracic Society 2015 | ||
| 650 | 4 | |a Biological Markers - blood | |
| 650 | 4 | |a Influenza, Human - epidemiology | |
| 650 | 4 | |a Antibodies, Viral - blood | |
| 650 | 4 | |a Immunity, Humoral - immunology | |
| 650 | 4 | |a Influenza Vaccines - administration & dosage | |
| 650 | 4 | |a Influenza, Human - prevention & control | |
| 650 | 4 | |a T-Lymphocytes - immunology | |
| 650 | 4 | |a Influenza A Virus, H1N1 Subtype - immunology | |
| 650 | 4 | |a Influenza, Human - blood | |
| 650 | 4 | |a Influenza, Human - immunology | |
| 650 | 4 | |a Original | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a pandemic influenza | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a T cells | |
| 700 | 1 | |a Begom, Shaima |4 oth | |
| 700 | 1 | |a Hoschler, Katja |4 oth | |
| 700 | 1 | |a Bermingham, Alison |4 oth | |
| 700 | 1 | |a Adamson, Walt |4 oth | |
| 700 | 1 | |a Carman, William |4 oth | |
| 700 | 1 | |a Riley, Steven |4 oth | |
| 700 | 1 | |a Lalvani, Ajit |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of respiratory and critical care medicine |d New York, NY : American Thoracic Society, 1994 |g 191(2015), 3, Seite 325-332 |w (DE-627)181994348 |w (DE-600)1180953-X |w (DE-576)03900032X |x 1073-449X |7 nnns |
| 773 | 1 | 8 | |g volume:191 |g year:2015 |g number:3 |g pages:325-332 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1164/rccm.201410-1798OC |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25506631 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1650213807 |
| 856 | 4 | 2 | |u http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4351579&tool=pmcentrez&rendertype=abstract |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2424 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4306 | ||
| 936 | r | v | |a XA 21200 |
| 951 | |a AR | ||
| 952 | |d 191 |j 2015 |e 3 |h 325-332 | ||